Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Slides:

Advertisements

Similar presentations

Volume 64, Issue 5, Pages (November 2013)

Advertisements

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 70, Issue 4, Pages (October 2016)

Volume 70, Issue 5, Pages (November 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 70, Issue 1, Pages (July 2016)

Volume 68, Issue 4, Pages (October 2015)

Volume 73, Issue 5, Pages (May 2018)

Volume 54, Issue 4, Pages (October 2008)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Advances in the Treatment of Metastatic Prostate Cancer

Volume 70, Issue 4, Pages (October 2016)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 64, Issue 5, Pages (November 2013)

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 67, Issue 2, Pages (February 2015)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 65, Issue 4, Pages (April 2014)

Volume 66, Issue 3, Pages (September 2014)

Volume 63, Issue 5, Pages (May 2013)

99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer Tobias Maurer, Stephanie Robu, Margret Schottelius,

Laurent Boccon-Gibod European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies Steven P. Rowe, Kenneth J.

European Urology Oncology

Volume 71, Issue 6, Pages (June 2017)

Volume 67, Issue 1, Pages (January 2015)

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Volume 62, Issue 6, Pages (December 2012)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

MET-Mutated NSCLC with Major Response to Crizotinib

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

Volume 71, Issue 5, Pages (May 2017)

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 71, Issue 4, Pages (April 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

European Urology Oncology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

European Urology Oncology

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

European Urology Oncology

Highlighting Unmet Needs: Real Patients, Difficult Choices

European Urology Oncology

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Metastatic Lung Cancer to the Pancreas

Axel Heidenreich European Urology Supplements

(A) Na18F PET images (maximum-intensity projection).

European Urology Oncology

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

Presentation transcript:

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer Rahul Aggarwal, Xiao Wei, Won Kim, Eric J. Small, Charles J. Ryan, Peter Carroll, Matthew Cooperberg, Michael J. Evans, Thomas Hope European Urology Oncology Volume 1, Issue 1, Pages 78-82 (May 2018) DOI: 10.1016/j.euo.2018.03.010 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Changes in PSMA uptake on PET from baseline by metastatic lesion. Maximum-intensity projection images from baseline 68Ga-PSMA-11 PET scans for each patient with (A) metastatic castration-sensitive prostate cancer and (B) metastatic castration-resistant prostate cancer. Up to seven metastatic lesions in bone and soft tissue were chosen for analysis. The change in SUVmax per lesion is shown below the image for each patient following treatment initiation with (A) androgen deprivation therapy (ADT) and (B) enzalutamide. Marks along the x-axis represent PSMA PET time points. ADT=androgen deprivation therapy; enz=enzalutamide; PET=positron emission tomography; PSMA=prostate-specific membrane antigen; SUV=standardized uptake value; W2=week 2; W4=week 4. European Urology Oncology 2018 1, 78-82DOI: (10.1016/j.euo.2018.03.010) Copyright © 2018 European Association of Urology Terms and Conditions